By establishing a CRGs-based prognosis model with the five hallmark genes (G6PD, PRR11, KIF20A, EZH2, and CDCA8), it brought prospective targets for determining the therapeutic efficacy of immunotherapy and targeted therapy, and accurately predicting the survival of HCC. The gene discussed is PRR11; the disease is hepatocellular carcinoma.